<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913142</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/21/0019</org_study_id>
    <secondary_id>2021-A00096-35</secondary_id>
    <nct_id>NCT04913142</nct_id>
  </id_info>
  <brief_title>About Oral and Gut Microbiota in Intensive Care Unit : SARS-CoV-2 (COVID-19) Infection Impact.</brief_title>
  <acronym>CO-MIC</acronym>
  <official_title>About Oral and Gut Microbiota in Intensive Care Unit : SARS-CoV-2 (COVID-19) Infection Impact. (CO-MIC Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present study is to describe the negative impact on oral and gut&#xD;
      microbiota of a severe acute respiratory syndrome SARS-CoV-2 infection in patients&#xD;
      hospitalized in intensive care units (ICU). The study would like to compare their microbiota&#xD;
      to the microbiota of ICU patients, non-infected by the SARS-CoV-2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gut microbiota in ICU patients is sorely distorted, there is an important loss of diversity&#xD;
      which can be traduced by a decrease of commensal bacteria and an increase of pathogens. The&#xD;
      virulence, infectivity, and transmissibility of the emerging SARS-Coronavirus 2 is a reason&#xD;
      for us to find strategies and therapeutics to curb the epidemic. Gut mucosa is very probably&#xD;
      a target for the virus and it seems likely that feces are a way of transmissibility. It&#xD;
      suppose too that gut microbiota is more weathered in patients with a SARS-CoV-2 infection,&#xD;
      moreover if they have to be hospitalized in ICU. For this reason, the present study would&#xD;
      like to collect oral and rectal swab from patients hospitalized in ICU for a serious&#xD;
      SARS-CoV-2 infection and from patients hospitalized in ICU for another reason that a&#xD;
      SARS-CoV-2 infection at day 1, each 7 days and at the end of their ICU stay. Other objectives&#xD;
      are to know if this distorted microbiota is a risk factor for poor outcomes in our ICU&#xD;
      patients, if antibiotics and artificial nutrition are too a risk factor of weathered&#xD;
      microbiota and finally if we can connect oral and rectal dysbiosis to use the oral dysbiosis&#xD;
      to predict the rectal dysbiosis in view of the ease to collect oral sample.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2021</start_date>
  <completion_date type="Anticipated">February 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>difference in bacterial DNA sequencing from oral and fecal samples</measure>
    <time_frame>day 1</time_frame>
    <description>difference in bacterial DNA sequencing from oral and fecal samples among ICU patients infected by the SARS-CoV-2 and ICU patients without SARS-CoV-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>difference in bacterial DNA sequencing from oral and fecal samples</measure>
    <time_frame>day 7</time_frame>
    <description>difference in bacterial DNA sequencing from oral and fecal samples among ICU patients infected by the SARS-CoV-2 and ICU patients without SARS-CoV-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>difference in bacterial DNA sequencing from oral and fecal samples</measure>
    <time_frame>day 14</time_frame>
    <description>difference in bacterial DNA sequencing from oral and fecal samples among ICU patients infected by the SARS-CoV-2 and ICU patients without SARS-CoV-2</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>SARS-CoV-2 Acute Respiratory Disease</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>patients not suffering from COVID-19 hospitalized in intensive care unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients COVID-19</arm_group_label>
    <description>patients suffering from COVID-19 hospitalized in intensive care unit</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal and oral samples</intervention_name>
    <description>oral and rectal swab from patients hospitalized at day 1, each 7 days and at the end of their ICU stay</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>patients COVID-19</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fecal and oral samples will be collected in each patient at the admission in intensive care&#xD;
      unit to analyze bacterial DNA and describe their microbiota&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients hospitalized in intensive care units (ICU)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Controls:&#xD;
&#xD;
        - Hospitalized patient with non-SARS-CoV-2 hypoxemic pneumonia&#xD;
&#xD;
        Patients COVID 19:&#xD;
&#xD;
        - Patient hospitalized for SARS-CoV-2 hypoxemic pneumonia&#xD;
&#xD;
        All:&#xD;
&#xD;
          -  Patient hospitalized for less than 48 hours in a general intensive care unit&#xD;
&#xD;
          -  Patient who has given free, informed and express (oral) consent to participate in the&#xD;
             research (or a close relative or trusted person of the patient if the patient cannot&#xD;
             express himself/herself)&#xD;
&#xD;
          -  Patient covered by a social security system or equivalent&#xD;
&#xD;
          -  Expected hospitalization of more than 48 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  gut inflammatory disease&#xD;
&#xD;
          -  recent gut surger&#xD;
&#xD;
          -  ostomy&#xD;
&#xD;
          -  recent antibiotics&#xD;
&#xD;
          -  artificial nutrition in the long term&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fanny BOUNES, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fanny BOUNES, MD</last_name>
    <phone>05 61 32 23 11</phone>
    <phone_ext>+33</phone_ext>
    <email>bounes.f@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fanny BOUNES, MD, PhD</last_name>
      <phone>+33 5 61 32 23 11</phone>
      <phone_ext>+33</phone_ext>
      <email>bounes.f@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>May 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID 19</keyword>
  <keyword>Critical care</keyword>
  <keyword>microbiota</keyword>
  <keyword>microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

